180 Life Sciences Corp Asset Resilience Ratio
180 Life Sciences Corp asset resilience ratio. 180 Life Sciences Corp (ATNF) has an Asset Resilience Ratio of 20.45% as of December 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ATNF cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of 180 Life Sciences Corp (2017–2019)
Asset resilience ratio of 180 Life Sciences Corp from 2017 to 2019. This chart shows how 180 Life Sciences Corp's Asset Resilience Ratio has changed over time. Read ATNF current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down 180 Life Sciences Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ATNF current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.30 Million | 20.45% |
| Total Liquid Assets | $10.30 Million | 20.45% |
Asset Resilience Insights
- Good Liquidity Position: 180 Life Sciences Corp maintains a healthy 20.45% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
180 Life Sciences Corp Industry Peers by Asset Resilience Ratio
Compare 180 Life Sciences Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
180 Life Sciences Corp Asset Resilience Ratio by Year (2017–2019)
180 Life Sciences Corp asset resilience ratio by year from 2017 to 2019. The table below shows the annual Asset Resilience Ratio data for 180 Life Sciences Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 22.89% | $11.88 Million | $51.88 Million | -76.71pp |
| 2017-12-31 | 99.60% | $116.59 Million | $117.06 Million | -- |
About 180 Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more